Thesis
Given Longboard Pharmaceuticals' recent FDA breakthrough designation for its epilepsy treatment and the impressive clinical data showing significant seizure reduction, I believe that LBPH's stock will exhibit upward momentum, presenting a high-risk, high-reward opportunity for short-term trading as the market responds to this positive news.